【摘要】 观察持续皮下胰岛素注射治疗(CSII)2型糖尿病。在给予短效胰岛素(Novolin R,42例)和给予人胰岛素类似物Insulin Aspart(46例)的5 d治疗中,2组在血糖控制上差异无统计学意义,InsulinAspart用量明显少于Novolin R。在CSII治疗2型糖尿病中,Insulin Aspart与Novolin R均安全有效,InsulinAspart用量少,优于Novolin R。更多还原

【Abstract】 The effect of continuous subcutaneous insulin injection (CSII) treatment in type 2 diabetic patients was observed. Forty-six cases and 42 cases were treated with Insulin Aspart (human insulin analogue) and Novolin R (human insulin) for 5 days, respectively. There was no difference in controlling blood glucose between two groups. Both Novolin R and Insulin Aspart during CSII treatment in type 2 diabetes were safe and efficient. The doses of Insulin Aspart were significantly lower than those of Novolin R, thus, it seems that the former was more efficient than the latter.更多还原